Basilea Pharmaceutica's quarterly market cap
increased
from Dec. 2024 (CHF499.9 Mil) to Jun. 2025 (CHF576.7 Mil) and
increased
from Jun. 2025 (CHF576.7 Mil) to Dec. 2025 (CHF672.4 Mil).
Basilea Pharmaceutica's annual market cap
increased
from Dec. 2023 (CHF423.7 Mil) to Dec. 2024 (CHF499.9 Mil) and
increased
from Dec. 2024 (CHF499.9 Mil) to Dec. 2025 (CHF672.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Basilea Pharmaceutica's Enterprise Value for Today is CHF571.8 Mil.
Basilea Pharmaceutica (XSWX:BSLN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Market Cap distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Basilea Pharmaceutica's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Market Cap of CHF642.3 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #320 out of 1429 companies in the Biotechnology industry, placing it in the top 22.4%.
Is Basilea Pharmaceutica's Market Cap too high?
Basilea Pharmaceutica's current Market Cap is CHF642.3 Mil. Based on the distribution chart, Basilea Pharmaceutica ranks #320 out of 1429 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #320 out of 1429 companies for Market Cap. This places Basilea Pharmaceutica in the top 22% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Market Cap is CHF642.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.38, compared to a current price of CHF51.90 — trading 9.6% below its estimated fair value. The current Market Cap is CHF642.3 Mil. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Market Cap is CHF642.3 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.90 is trading 9.6% below its estimated GF Value™ of CHF57.38.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Market Cap: CHF642.3 Mil
GF Value™: CHF57.38 vs. price of CHF51.90 (9.6% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for XSWX:BSLN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
